Beyond Conventional Therapies: Molecular Dynamics of Alzheimer's Treatment through CLOCK/BMAL1 Interactions

Conclusion: A novel therapeutic approach emerges, suggesting the combination of melatonin with Lecanemab as a monoclonal antibody therapy. Importantly, prior research has not explored the effects of FDA-approved drugs on Bmal1 expression or their potential for synergistic effects.PMID:38509675 | DOI:10.2174/0115672050301014240315065235

Source: Current Alzheimer Research - March 21, 2024 Category: Neurology Authors: Ismail Celil Haskologlu Emine Erdag Ahmet Ozer Sehirli Orhan Uludag Nurettin Abacioglu Source Type: research